Comparative Pharmacology
Head-to-head clinical analysis: NALLPEN IN PLASTIC CONTAINER versus PEN VEE K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALLPEN IN PLASTIC CONTAINER versus PEN VEE K.
NALLPEN IN PLASTIC CONTAINER vs PEN-VEE K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nallpen is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically active against beta-lactamase-producing Staphylococcus aureus.
Penicillin V binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis.
Nafcillin 1-2 g IV every 4 hours for moderate to severe infections; for MSSA bacteremia or endocarditis, 2 g IV every 4 hours.
250-500 mg orally every 6-8 hours for mild to moderate infections; up to 2 g/day for severe infections.
None Documented
None Documented
0.9-1.2 hours; prolonged in renal impairment (up to 7-10 hours in anuria); requires dose adjustment for CrCl <30 mL/min
Terminal elimination half-life: 30-60 minutes in adults with normal renal function, prolonged to 3-10 hours in severe renal impairment.
Primarily renal (60-80% unchanged drug via glomerular filtration and tubular secretion); biliary/fecal: minor (<5%)
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 60-90% of elimination; biliary/fecal elimination is minimal (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic